Longitude Capital specializes in making venture investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches.
Since 2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties and other equity and equity-linked instruments.
Following an initial investment, they work closely with our portfolio companies and syndicate partners to develop and implement strategic plans, achieve key operating objectives, build world class teams, raise capital and pursue liquidity opportunities in a manner that optimizes returns to key stakeholders. For more information, please visit www.longitudecapital.com.